Lilly is set to acquire Ajax Therapeutics for up to $2.3B, adding a novel JAK2 inhibitor to bolster its oncology pipeline. The deal targets unmet needs in myeloproliferative neoplasm (MPN) treatment and signals a deeper push into oncology. The transaction is strategically positive for Lilly and could be meaningful for the biotech sector.
Lilly is set to acquire Ajax Therapeutics for up to $2.3B, adding a novel JAK2 inhibitor to bolster its oncology pipeline. The deal targets unmet needs in myeloproliferative neoplasm (MPN) treatment and signals a deeper push into oncology. The transaction is strategically positive for Lilly and could be meaningful for the biotech sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.58
